Sellames and Next and Bio Collaborate on Brain Organoid Production and Quality Control

Combination of Brain Organoid Cultivation Technology and Sellames HD-MEA-Based Electrophysiological Analysis System

Promoting Stable Mass Production Through Standardized Functional Validation and Quality Control (QC)

"Expectations for Expanded Application of Brain Organoid-Based Drug Development and NAMs (New Approach Methodologies) as Alternatives to Animal Testing"

Sellames, which possesses electrophysiological analysis technology, and Next and Bio, an organoid company, will collaborate to establish a brain organoid production and quality control (QC) system.

Cellames recently signed a business agreement with NextnBio, an organoid-based biotechnology company, to establish systems for brain organoid production and quality control. Representatives from both companies are taking a commemorative photo at the signing ceremony. Cellames

On March 4, Sellames announced that it had signed a memorandum of understanding (MOU) with Next and Bio to build a brain organoid production and QC system. The purpose of this agreement is to standardize the functional validation and quality control processes of brain organoids and to establish a stable mass production system.

Next and Bio produces experimental brain models based on its brain organoid cultivation technology. Sellames analyzes neural activity in organoids by applying a high-density microelectrode array (HD-MEA)-based electrophysiological measurement system.

The HD-MEA system is a technology that can non-invasively measure action potentials generated within the neural networks of brain organoids. Through this, it is possible to quantitatively evaluate the functional characteristics of organoids. The company explained that this technology can be used to establish a quality verification system during the brain organoid production process.

Brain organoids are three-dimensional cellular models that partially mimic the structure and function of human brain tissue. Recently, their potential is being discussed as models for New Approach Methodologies (NAMs), which serve as alternatives to animal testing for drug toxicity evaluation and disease research. However, it has been pointed out that, for both research and industrial applications, it is necessary to have technology that enables stable production of organoids with uniform quality.

Next and Bio is building a platform to produce organoids with standardized size and quality based on its organoid cultivation technology. The company is currently collaborating with the Cancer Science Institute of Singapore to establish a large-scale organoid library.

Both companies plan to pursue joint research and development through this collaboration and seek to expand research and industrial applications based on brain organoids.

This content was produced with the assistance of AI translation services.